The potential impact on patient outcome of different Minimal residual disease (MRD) levels at time of transplant in patients with lymphoblastic leukemia undergoing allogeneic hematopoietic SCT (HSCT) remains uncertain. In this study, we quantified MRD levels at time of transplant using multiparameter flow cytometry (MFC). Mononuclear cells from marrow aspirates were obtained from 102 adult and child patients before their conditioning regimen. Quantification of MRD levels was carried out by detecting patient-specific leukemia-associated immunophenotypes using four-color MFC. Thirty patients exhibited measurable levels of MRD at the time of transplant, with low levels (0.01 to p0.1%) in 12 cases, intermediate levels (40.1 to p1%) in 8 cases and high levels (41%) in 10 cases. The leukemia-free survival (LFS) rates were 65.9±7.0%, 42.9±15.7% and 0% for negative, low levels p0.1% and intermediate-high levels 40.1%, respectively (Po0.001, log-rank test). Overall survival (OS) was 52.3 ± 7.6%, 28.6 ± 13.8% and 0% for MRD-negative, low levels p0.1% and intermediate-high levels 40.1%, respectively (Po0.001, log-rank test). Multivariate Cox analysis confirmed that detection of leukemia cells by flow cytometry at transplant was the most significantly adverse factor for OS, LFS and EFS after transplant.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HSCT) is the most intensive form of treatment for ALL. 1 HSCT from related or unrelated human leukocyte Ag (HLA)-compatible donors clearly benefits ALL patients with poor-risk factors at diagnosis, such as adverse cytogenetic abnormalities (that is, Philadelphia chromosome). HSCT is also recommended for either patients with a suboptimal response after risk-adjusted treatment or patients suffering from an overt leukemia-relapse. 1 Results using alternative stem cell sources or alternative donors have improved in the last decade, and current outcomes after HSCT are strongly correlated with clinical disease status. [2] [3] [4] [5] The optimal results in both children and adults are obtained when patients underwent HSCT at early stages of the disease as measured by conventional morphological remission. [5] [6] [7] Over the last decade, the concept of remission in ALL has evolved owing to use of molecular techniques and multiparameter flow cytometry (MFC) to more precisely track residual leukemic cells during chemotherapy treatment. MFC provides valuable, dynamic information in addition to all known clinical variables and, most importantly, significantly correlates to clinical outcomes. [8] [9] [10] Slow clearance of leukemia cells (that is, X1% at the end of induction therapy) identifies patients at the highest risk of relapse, and intensification therapy (including HSCT) is indicated at this point. 10 However, pooled data from measurements of MRD levels in pediatric patients by molecular techniques indicate that the optimal benefit of HSCT is observed in MRD-negative patients. [11] [12] [13] [14] [15] [16] [17] [18] Three studies on HSCT in high-risk myeloid or lymphoblastic leukemia in children showed that the disease status and MRD detection at transplant measured by MFC are the most important adverse factors for outcome. [19] [20] [21] A recent study of adult patients undergoing myeloablative HSCT for ALL demonstrates that pre-transplantation evidence of MRD, especially when detected by MFC, was associated with both lower OS and lower relapse-free survival. 22 However, the prognostic impact based on different MRD levels is not well established. Indeed, the prognosis impact of high levels of MRD before HSCT greatly varies among studies and techniques ranging from 0 to 41% [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] for EFS. Therefore, it remains unclear at which MRD level that allogeneic HSCT could still provide curative potential.
In this observational study, we aimed to determine the prognosis significance of different MRD levels by MFC on the outcome of both adults and children after receiving myeloablative HSCT in a large series of patients with a long-term follow-up.
DESIGN AND METHODS
From March 1999 to October 2010, a total of 106 consecutive patients were diagnosed with ALL undergoing HSCT at our institution. Of this group, 102 were included in this cohort study for retrospective analysis of the following inclusion criteria: (i) complete morphological remission (less than 5% of blast cells over total marrow cells, reviewed by two morphologists); (ii) MFC study available in marrow aspirate obtained within a maximum of 28 days before the administration of myeloablative conditioning regimen; and (iii) the presence of a leukemia-associated 1 Hematology and Bone Marrow Transplantation Department, University Hospital 'Reina Sofia', Cordoba, Spain and phenotype at diagnosis and/or last relapse. Two patients were excluded because of the presence of more than 5% of blast cells, one patient owing to the lack of leukemia-associated phenotype and one patient owing to the lack of a marrow aspirate within the defined period. No chemotherapy was administered between MRD testing and HSCT. Out of the 102 patients, 53 (52%) underwent HSCT in first CR. Indication criteria for transplant in first CR were as follows: high-risk features at diagnosis (N ¼ 44), slow morphological clearance at þ 14 day of induction chemotherapy and/or slow MRD clearance at þ 30 day (N ¼ 9). In nineteen children (younger than 14 years) HSCT was performed in first CR owing to presence of BCR-ABL gene rearrangement (N ¼ 9), MLL gene rearrangements (N ¼ 2), T-lineage ALL with hyperleukocytosis at diagnosis (N ¼ 3), slow response at day þ 14 (N ¼ 2), and B-lineage ALL with hyperleukocytosis and other poor prognosis features such as age 15 months or central nervous system (CNS) involvement (N ¼ 3). Among the 33 patients undergoing HSCT in second CR, 25 (75.8%) had suffered marrow relapse, 4 (12.1%) had isolated extramedular relapse (2 testis and 2 CNS), and 4 (12.1%) had both marrow and extramedular relapses (2 testis and 2 CNS). The median time from diagnosis to relapse was 27 months (range 6-176). Among the 16 patients who underwent HSCT for advanced disease, 8 (50%) had experienced two marrow relapses, 6 (18.1%) had combined marrow and extramedulary relapses and 2 patients (12.5%) had isolated CNS relapses.
Data from the first 16 patients in this study have been previously reported, 23 and three patients underwent a second HSCT procedure from different donors. Clinical features are detailed in Table 1 . 
Detection of marrow leukemic cells by multiparameter flow cytometry
Mononuclear cells were isolated by Ficoll-Hypaque (Lymphoprep, Nycomed, Oslo, Norway) density gradient centrifugation and washed three times in PBS. Combinations of monoclonal antibodies against surface, cytoplasmic or nuclear leukocyte Ags defining leukemia-associated immunophenotypes and staining techniques have been previously reported. 23, 24 Combinations included one or two markers that identify immature lymphoid progenitor (that is, CD19, CD34 or CD10) in addition to one marker not expressed on normal lymphoid progenitors, such as myeloid Ag. Simultaneous expression of markers normally present at discrete stages of differentiation was also used, and the intensity of Ag expression (especially for CD10, CD34, CD45 and CD38) allowed for clear differentiation between ALL blast cells and their normal counterparts. For T-ALL, the presence of double-positive cells for CD3 and TdT was restricted to blast cells because their normal counterparts are only found in thymus. For cases lacking TdT expression, the combination of CD34 and CD3cyt was used. (Online Supplementary Table S1 ). MRD markers were determined a priori when patient's blast cells were available (N ¼ 49) at our institution. For referred patients from other hospitals (N ¼ 53), a complete standard panel was used. The commercially available reagents used were mostly mouse anti-human monoclonal antibodies (MnAb) labelled with FITC, phycoerythrin, peridinin-chlorophyll-protein and allophycocyanin. The following MnAbs were used to define leukemiaassociated immunophenotypes by four-color MFC: CD38 (IgG1, clone TI16), CD10 (IgG1, Clone ALB1), CD20 (IgG1 Clone2H7), CD45 (clone HI30, Pharmingen), Anti-TdT (Clone HT-6), CD66c (IgG1, Clone Kat4c from Dako, Denmark and clone B6.2/CD66c from Becton-Dickinson, San Jose, CA), CD3 (IgG1, Clone UCHT1), CD19 (IgG1 Clone HD37), CD13 (IgG1 Clone WM-47), CD33 (IgG1, Clone WM-54) (Dako, Glostrup, Denmark), CD15 (IgM, Clone MMA), CD34 (IgG1 Clone HPCA2), CD58 and anti-human HLA-DR (IgG2a, Clone L243 from Becton Dickinson).
A dual laser FACScalibur flow cytometer with Cell Quest Software (Becton Dickinson) was used until March 2008; thereafter, a FACScanto II with FACSDiva software was used. Events comprising a homogeneous cluster were expressed as a percentage of total run cells. Sensitivity and quality controls have also been previously reported. 23, 24 Briefly, leukemia blast cells from representative patients with B-lineage ALL (N ¼ 5) and T-lineage ALL (N ¼ 5) were mixed with normal BM cells at a tenfold serial dilution, then followed by staining procedures. Acquisition and analysis of 2-5 Â 10 5 cells per tube generated a clearly detectable cluster at 0.01% level. No phenotypically abnormal clusters were detected after running up to 5 Â 10 6 cells from regenerating marrow samples after HSCT from patients not diagnosed with ALL.
Statistical analysis. OS was measured from the time of hematopoietic infusion to the date of death. Leukemia-free survival (LFS) was measured from the time of hematopoietic cell infusion to the date of leukemia relapse defined as more than 5% of lymphoblast marrow count (or at a lower percentage but unambiguously classified as leukemia cells by flow cytometry) or extramedullary relapse. EFS was defined as the time from hematopoietic infusion to the first event (leukemia relapse marrow, extramedullary relapses and/or death from either disease progression or transplant-related mortality). w 2 and Fisher's exact tests were used to compare clinicopathological parameters among patients with different MRD levels. Student's t-test was chosen for comparison of continuous variables. Cumulative actuarial probabilities (plus or minus standard errors) of EFS, OS and LFS were calculated using the Kaplan-Meier estimator, and survival rates were those found at the time the last event was censored. Differences between time-to-event distribution function were compared by the log-rank test. Results were analyzed and updated until 1 June 2012, 
RESULTS
At the last follow-up, 35 patients had experienced a leukemia relapse after HSCT (22 marrow relapses, 1 isolated extramedullary relapse, 12 combined extramedullary and marrow relapses). At the last follow-up, 54 (52.9%) patients had died of leukemia progression and/or transplant-related mortality. The median follow-up post-transplantation for 48 living patients was 60.8 months (range: 12.4-140.9).
MRD-levels pre-HSCT and correlation with clinical variables In 72 (70.6%) patients, we did not detect leukemia cells in mononuclear marrow cells form aspirates obtained before conditioning regimen (MRD-negative defined as lack of unambiguous cluster at 0.01% level). However, 30 patients (29.4%) still had lymphoblastic leukemia-cells at the time of transplant defined by a patient-specific leukemia-associated immunophenotype with a median of 0.25% over total marrow mononuclear cells (range, 0.01-6%). Among them, 12 (40%) had MRD low levels ranging from 0.01 to p0.1%, 8 (26.7%) had intermediate levels ranging from 0.1 to p1% and 10 (33.3%) had the highest levels defined as more than 1%.
Comparison of clinical characteristics of MRD-negative patients (N ¼ 72) and patients with either low (p0.1%, N ¼ 12) or intermediate-high (40.1%, N ¼ 18) MRD levels are detailed in Table 2 .
Despite the statistical limitations due to the small number of patients in each cohort, we did not find significant differences among these three groups when comparing clinical variables at diagnosis (that is, sex, WBC count or BCR-ABL) and pre-transplant characteristics such as donor-type, time from diagnosis to transplant, stem cell source, conditioning regimen or GVHD prophylaxis. All patients showing MRD levels higher than 0.1% had been diagnosed with B-lineage ALL. Thus, MRD levels were significantly associated with disease status. Intermediate-high MRD levels (40.1%) were only found in 6/53 (11%) of patients grafted in first CR whereas these levels were detected in 12/49 (24%) of patients in more advanced disease undergoing HSCT. When considering only intermediate MRD-positive levels (0.01 to p0.1%), we did not find significant differences among patients undergoing HSCT in either 1st CR or more advanced disease.
Clinical outcome of patients undergoing HSCT based on MRD levels Clinical outcome for patients with detectable MRD at any level (N ¼ 30) was poor with 20.8 ± 9.1%, 10.7% ± 5.8 and 3.8 ± 3.7% for LFS, OS and EFS respectively.
MRD levels at HSCT have a significant impact on the post-HSCT outcome in adults and children. Patients with intermediate-high MRD levels (more than 0.1% of leukemia cells) had a dismal prognosis in our studies. LFS was 65.9 ± 7.0%, 42.9 ± 15.7% and 0% for MRD-negative, MRDp0.1% and MRD40.1%, respectively (Po0.001, log-rank test). OS was 52.3 ± 7.6%, 28.6 ± 13.8% and 0% for MRD-negative, MRDp0.1% and MRD40.1%, respectively (Po0.001, log-rank test). Finally, EFS was 50.2±7.3%, 11.1±10.7% and 0% for MRD-negative, MRDp0.1% and MRD40.1%, respectively (Po0.001, log-rank test). Survival curves for LFS and OS are shown in Figure 1 . Moreover, when considering only MRD-positive patients, OS was significantly superior in patients with low levels (p0.1%) than those with intermediate-high levels 40.1% (28.6% ± 13.7 vs 0%, P ¼ 0.0153). Likewise, LFS and EFS were superior in patients with low MRD levels (42.9% ± 15.7 and 11.1 ± 10.7%, respectively) compared with intermediate-high levels (0% for both measures), although these differences did not reach statistical differences.
When considering patients in first CR (N ¼ 53), or beyond first CR (N ¼ 49) separately, the impact of different MRD levels remained unchanged. Survival curves for OS and LFS are detailed in Figure 2 .
Univariate and multivariate analyses of LFS, EFS and OS in adult and child ALL patients undergoing HSCT The following variables were included in univariate and multivariate analyses for outcomes (EFS, OS and LFS) within the global Prognostic value MRD levels at HSCT by MFC in ALL J Sanchez-Garcia et al series (N ¼ 102): age at HSCT (younger or older than 14 years), sex, ALL-lineage (B or T), WBC at diagnosis (less or more than 50 000/mL), adverse cytogenetic (BCR-ABL gene rearrangement, MLL gene rearrangement, haploid karyotypes p44 chromosomes or complex karyotypes), disease status at HSCT (first, second or 4second CR and dichotomic, first or Xsecond CR), time from diagnosis to HSCT (less or more than 12 months), donor type (HLA-identical sibling donor or alternative donor), stem cell source (cord blood or marrow/peripheral blood), conditioning regimen (with or without TBI), GVHD prophylaxis (CsA plus MTX or alternative schemes), presence or absence of grades II-IV acute GVHD and MRD result pre-HSCT (negative or positive at any level).
In the univariate analyses, the MRD levels at the time of HSCT was the only variable that showed a statistically significant negative correlation in all outcome measures: EFS (HR 5.61; 95% CI 3.2 to 9.83, Po0.001), OS (HR 4.45; 95% CI 2.55 to 7.77, Pp0.001) and LFS (HR 6.84; 95% CI 3.31 to 14.12, Pp0.001). Older patients (age414 years) also had a more significant poor prognosis for OS (HR 2.1; 95% CI 1.20 to 3.69, P ¼ 0.009). Other clinical factors associated with a significantly adverse LFS in univariate analyses were as follows: time from diagnosis to HSCT longer than 12 months (HR 2.10; 95% CI 1.05 to 4.18, P ¼ 0.03) and disease status Xsecond CR (HR 3.33; 95% CI 1.56 to 7.11). Development of grades II-IV acute GVHD was associated with a significantly longer LFS (HR 0.48; 95% CI 0.24 to 0.96, P ¼ 0.038), as expected.
The results of the multivariate Cox proportional hazard regression analyses for EFS, OS and LFS are summarized in Table 3 . Positive MRD levels at the time of transplant remained the only statistically significant prognostic factor for EFS (HR 5.19; 95% CI 2.87 to 9.39, Po0.001). Positive MRD levels at HSCT and increased age (414 years) negatively impacted OS. Detection of leukemia cells by MFC at the time of HSCT and advanced disease status (Xsecond CR) remained the most statistically significant adverse factors for LFS, whereas the development of grades II-IV acute GVHD was associated to a significantly decreased probability of leukemia relapse.
Post-HSCT follow-up of MRD-positive patients The median time from HSCT to relapse was longer for patients with MRD low levels p0.1% than for patients with intermediate-high MRD levels 40.1% (8.5 months vs 4.6 months, respectively). Dot plots from three representative patients with low, intermediate and high MRD levels are displayed in Figure 3 . Fifteen patients underwent preemptive therapeutic interventions based on increasing MRD levels post-transplantation as detected by MFC: cyclosporine withdrawal (N ¼ 9), donor lymphocyte infusions (N ¼ 5) and imatinib therapy (N ¼ 1). Out of these, only three patients, all with pre-HSCT MRD levels p0.1%, achieved sustained CR.
DISCUSSION
To date, several clinical variables such as age, disease status, time from diagnosis to transplant, donor type and GVHD had been considered to impact outcome in ALL patients undergoing HSCT. However, our results firmly demonstrate that the detection of submicroscopic leukemia cells by flow cytometry is a strong predictor for the outcomes in both adults and children. These data, together with the cumulative evidence of the adverse prognosis of the detection of MRD by molecular techniques in children population, suggests that the MRD status at the time of HSCT should be included in all clinical studies when analyzing HSCT results for childhood and adult ALL.
Additionally, one of the most relevant consequences of this study establishes the importance of varying MRD levels on the outcome after HSCT. Patients with MRD levels p0.1% still have a chance for long-term remission with EFS of 11%, but those with measurable MRD levels over 0.1% have a dismal prognosis based on our study. This finding reflects the inability of myeloablative HSCT to eradicate a measurable burden of leukemia cells, even at submicroscopic levels. Neither the conditioning regimen nor the potential graft-versus-host leukemia effect can eliminate leukemia cells that are intrinsically resistant to previous poly-chemotherapy regimens. However, it is important to highlight that our series is unicentric and data come from a retrospective analysis of a heterogeneous group of patients. Compared with data reported by other authors using molecular techniques for MRD quantification, [11] [12] [13] [14] [15] [16] [17] [18] 25 the EFS for patients with high MRD levels pre-HSCT had a wide range from 0 to 41%, reflecting the heterogeneity of conditioning regimens, the use of T-cell-depleted grafts and differences in MRD-detection methodologies. It is worth noting that none of the patients in our study received a T-cell-depleted graft and that we did not observe significant differences in LFS when comparing a TBI-based conditioning regimen with no TBI (used mostly in UC HSCT) for either the global study or MRDpositive patients.
It has been reported that molecular and cytometric techniques can yield comparable results at 10 À 4 sensitivity level 26 and standardization-validation studies to detect MRD have been performed for both tecniques. 27 MFC is used more extensively Prognostic value MRD levels at HSCT by MFC in ALL J Sanchez-Garcia et al at transplantation centers probably because of the availability of multicolor flow-cytometers. However, MFC has disadvantages: fluctuations in Ag expression and lack of expertise interpretation of results. It is important to note that a substantial proportion of MRD-negative patients, assessed by four-color MFC at the time of HSCT, still relapse after transplantation, suggesting that molecular techniques yielding more sensitivity level could more precisely detect which patients are at high risk for relapse allowing MRD-driven interventions to be applied earlier. Additionally, improvements in multicolor flow cytometry could improve threshold for MRD detection. 28 For patients who are MRD-positive at the time of HSCT, additional chemotherapy treatment before HSCT can be cautiously considered, provided that this treatment does not add significant toxicity that could impair the post-HSCT outcomes by increasing non-relapse mortality due to organ damage or fungal infection. Alternative options include a more specific and targeted treatment and the use of blinatumomab, a bispecific T-cell engaging and anti-CD19 MAb, that can enhance T-lymphocyte cytotoxicity against MRD, which has been recently reported with promising results. 29 The use of TBI-based conditioning regimen and the use of rapamycin-based GVHD prophylaxis have been proven to be associated to a reduced risk of leukemia relapse, 30 but their role in the prognosis of MRD-positive patients undergoing HSCT is unknown.
Regarding post-transplantation therapies to prevent relapse, a subset of patients with increasing chimerism or MRD levels after HSCT have been reported to benefit from early withdrawal of immunosuppressants or donor lymphocyte infusion. 29, 31 It has also been reported that the development of chronic GVHD was associated with an increased LFS in MRD-positive patients; however, in our study, preemptive immunotherapy measures could be applied to o50% of relapsing patients (abrupt relapses without previous MRD detection or increasing mixed chimerism, relapse once immunosuppression had been withdrawn or donorlymphocytes were unavailable in cord blood transplants) and only three patients achieved a sustained CR. Additionally, our group has previously reported that both normal and leukemic B-lymphopoiesis were nonspecifically inhibited during GVHD, but this effect was unable to control leukemia relapse. 24 It is plausible that the use of donor-derived T-lymphocytes against potential leukemia-associated Ags such as WT1, BCR-ABL or mHA could enhance results and improve immunological approaches to prevent impending leukemia relapse after HSCT. 32 In summary, we conclude that measurement of MRD levels at the time of transplant by MFC provides powerful prognostic information in both adult and child ALL patients undergoing HSCT. In our study, patients with MRD levels 40.1% have a dismal prognosis after HSCT.
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